Literature DB >> 31632748

Indications for lung transplant referral and listing.

Omar Shweish1, Goutham Dronavalli1.   

Abstract

Lung transplantation is a valuable therapeutic option for many patients with severe lung disease who have exhausted other medical or surgical therapies. However, since lungs are not a manufacturable organ like artificial heart valves or left ventricular assist devices, and since they are a limited resource compared to number of patients requiring the organs, the Department of Health and Human Services set the Final Rule of organ allocation in 1998. This led to development and implementation of Lung Allocation Score (LAS) in 2005. The score broadly divides lung diseases into 4 diagnostic criteria with a coefficient factor given to each category. The score is based on the prognostic factors of each patient to determine the risk of mortality without a transplant combined with the probability of patient survival post-transplant. Most of the guidelines for "Indications for referral and listing in lung transplant" is based on consensus opinion as there is limited amount of robust data and trials about this topic. The International Society for Heart and Lung Transplant (ISHLT) has published three editions for candidate selection and listing. In this article, we have attempted to highlight the guidelines and incorporated other disease specific prognostic factors that are not captured in the LAS. Ultimately, there are other factors like geographic location, height, blood group, preformed antibodies, transplant center experience, past wait times and transplant rate, availability of organs, etc., which also play a role especially when considering listing a patient for lung transplant. We also highlighted a representative disease in each category and most criteria for that disease will apply to other diseases in that category. Finally, this article does not delve into the history and reasoning behind each guideline but is meant to provide a general overview of indications and contraindications applicable in the field of adult lung transplantation. 2019 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Lung transplantation; candidate selection; lung transplant guidelines

Year:  2019        PMID: 31632748      PMCID: PMC6783714          DOI: 10.21037/jtd.2019.05.09

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  79 in total

1.  Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation.

Authors:  Michael Patrick Tuppin; Jennifer D Paratz; Angela T Chang; Helen E Seale; James R Walsh; Fiona D Kermeeen; Keith D McNeil; Peter M Hopkins
Journal:  J Heart Lung Transplant       Date:  2008-05-19       Impact factor: 10.247

2.  Direct bilirubin: A new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension.

Authors:  Xi-Qi Xu; Zi-Chao Lv; Qian-Qian Liu; Qin-Hua Zhao; Yan Wu; Kai Sun; Xin Jiang; Lan Wang; Fu-Hua Peng; Zhi-Cheng Jing
Journal:  Int J Cardiol       Date:  2016-11-07       Impact factor: 4.164

Review 3.  Risk assessment in pulmonary arterial hypertension.

Authors:  Amresh Raina; Marc Humbert
Journal:  Eur Respir Rev       Date:  2016-12

4.  Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.

Authors:  Ganesh Raghu; Luca Richeldi; Alexandre Jagerschmidt; Valerie Martin; Arun Subramaniam; Marie-Laure Ozoux; Corinne A Esperet; Christina Soubrane
Journal:  Chest       Date:  2018-12       Impact factor: 9.410

Review 5.  Predictors of mortality in COPD.

Authors:  Bartolome R Celli
Journal:  Respir Med       Date:  2010-04-22       Impact factor: 3.415

6.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.

Authors:  Alfred Fishman; Fernando Martinez; Keith Naunheim; Steven Piantadosi; Robert Wise; Andrew Ries; Gail Weinmann; Douglas E Wood
Journal:  N Engl J Med       Date:  2003-05-20       Impact factor: 91.245

7.  Improved quality of life after lung transplantation in individuals with cystic fibrosis.

Authors:  Karin M Vermeulen; Wim van der Bij; Michiel E Erasmus; Eric J Duiverman; Gerard H Koëter; Elisabeth M TenVergert
Journal:  Pediatr Pulmonol       Date:  2004-05

8.  Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.

Authors:  Brett Ley; Williamson Z Bradford; Eric Vittinghoff; Derek Weycker; Roland M du Bois; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

9.  A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.

Authors:  Sergio Harari; Antonella Caminati; Venerino Poletti; Marco Confalonieri; Stefano Gasparini; Donato Lacedonia; Fabrizio Luppi; Alberto Pesci; Alfredo Sebastiani; Paolo Spagnolo; Carlo Vancheri; Elisabetta Balestro; Martina Bonifazi; Stefania Cerri; Federica De Giacomi; Rossana Della Porta; Maria Pia Foschino Barbaro; Annalisa Fui; Patrizio Pasquinelli; Roberta Rosso; Sara Tomassetti; Claudia Specchia; Paola Rottoli
Journal:  Respiration       Date:  2018-03-27       Impact factor: 3.580

10.  Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010-2014.

Authors:  Jennifer Adjemian; Kenneth N Olivier; D Rebecca Prevots
Journal:  Ann Am Thorac Soc       Date:  2018-07
View more
  2 in total

1.  Waiting time and mortality rate on lung transplant candidates in Japan: a single-center retrospective cohort study.

Authors:  Takashi Hirama; Miki Akiba; Tatsuaki Watanabe; Yui Watanabe; Hirotsugu Notsuda; Hisashi Oishi; Hiromichi Niikawa; Yoshinori Okada
Journal:  BMC Pulm Med       Date:  2021-11-29       Impact factor: 3.317

Review 2.  Addressing Race in Pulmonary Function Testing by Aligning Intent and Evidence With Practice and Perception.

Authors:  Nirav R Bhakta; David A Kaminsky; Christian Bime; Neeta Thakur; Graham L Hall; Meredith C McCormack; Sanja Stanojevic
Journal:  Chest       Date:  2021-08-24       Impact factor: 9.410

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.